OZAGREL

/static/temp/default.svg Search structure
Synonyms
Status
Molecule Category UNKNOWN
UNII L256JB984D
EPA CompTox DTXSID6048547

Structure

InChI Key SHZKQBHERIJWAO-AATRIKPKSA-N
Smiles O=C(O)/C=C/c1ccc(Cn2ccnc2)cc1
InChI
InChI=1S/C13H12N2O2/c16-13(17)6-5-11-1-3-12(4-2-11)9-15-8-7-14-10-15/h1-8,10H,9H2,(H,16,17)/b6-5+

Physicochemical Descriptors

Property Name Value
Molecular Formula C13H12N2O2
Molecular Weight 228.25
AlogP 2.03
Hydrogen Bond Acceptor 3.0
Hydrogen Bond Donor 1.0
Number of Rotational Bond 4.0
Polar Surface Area 55.12
Molecular species ACID
Aromatic Rings 2.0
Heavy Atoms 17.0

Bioactivity

Mechanism of Action Action Reference
Thromboxane-A synthase inhibitor INHIBITOR PubMed PubMed
Protein: Thromboxane-A synthase
Description: Thromboxane-A synthase
Organism : Homo sapiens
P24557 ENSG00000059377
Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Enzyme Cytochrome P450 Cytochrome P450 family 5 Cytochrome P450 family 5A Cytochrome P450 5A1
- 24-10000 - - 89-89
Enzyme Oxidoreductase
- - - - 21-24
Assay Description Organism Bioactivity Reference
In vivo inhibitory effect on airway constriction induced by histamine 2-5 micro g/kg iv at 1 min after 10 mg/kg intravenous dose in anesthetized guinea pigs Cavia porcellus 0.0 %
In vivo inhibitory effect on airway constriction induced by histamine 2-5 micro g/kg iv at 1 min after 10 mg/kg iv dose of compound Cavia porcellus 0.0 %
Inhibitory activity of the compound against Thromboxane TXB2 production in human whole blood Homo sapiens 10.0 nM
Inhibition of thromboxane B2 production in whole blood of rat 15 min after intravenous injection of compound at 0.1 mg/kg Rattus norvegicus 89.0 %
Inhibition of thromboxane B2 production in whole blood of rat 45 min after intravenous injection of compound at 0.1 mg/kg Rattus norvegicus 72.0 %
Inhibition of thromboxane B2 production in whole blood of rat 75 min after intravenous injection of compound at 0.1 mg/kg Rattus norvegicus 46.0 %
Inhibition of thromboxane B2 production in whole blood of rats 1 hr following 1 mg/kg p.o. Rattus norvegicus 91.0 %
Inhibition of thromboxane B2 production in whole blood of rats, 3h after a peroral dose of 1.0 mg/kg Rattus norvegicus 42.0 %
Inhibition of thromboxane B2 production in whole blood of rats, 6 hr after a peroral dose of 1.0 mg/kg Rattus norvegicus 11.0 %
Tested ex vivo against serum TXB2 production at 1 hr after oral dose of 3 mg/kg of drug to rat Rattus norvegicus 86.0 %
Tested ex vivo against serum TXB2 production at 1 hr after oral dose of 30 mg/kg of drug to rat Rattus norvegicus 92.0 %
Tested in vitro against TXA2 synthetase inhibitory activity in human microsome None 60.0 nM
Tested in vitro against TXA2 synthetase inhibitory activity in human platelet None 300.0 nM
Tested in vitro against TXA2 synthetase inhibitory activity in human whole blood None 900.0 nM
Tested in vitro against rabbit thromboxane A2 synthetase (TXA2) at 1 uM Oryctolagus cuniculus 89.0 %
Tested ex vivo against TXA2 production in rat serum at 1 hr after peroral dose of 30 mg/kg and anesthetized with ether None 92.0 %
Tested in vitro against TXA2 synthetase inhibitory activity in rat platelet None 200.0 nM
Tested in vitro against TXA2 synthetase inhibitory activity in rat whole blood None 200.0 nM
In vitro inhibition of thromboxane-A2 synthase in rat whole blood during clotting at 37 degrees Centigrade None 640.0 nM
Tested for inhibition of thromboxane A2 (TXA2) production in rabbit by in vitro assay at 1 uM Oryctolagus cuniculus 89.0 %
Tested for inhibition of thromboxane A2 (TXA2) production in rat serum by ex vivo assay after peroral dose of 30 mg/kg None 92.0 %
In vitro inhibition of TXB2 production by incubating prostaglandin H2 with human platelet microsomes. None 24.0 nM
Thromboxane A2 synthase inhibitory activity was measured from inhibition of thromboxane B2 production in human platelet microsomes None 24.0 nM
In vitro inhibition of thromboxane synthase (TXA2) in human platelet microsomes [reduced formation of TXB2 from prostaglandin H2(PGH2)] None 24.0 nM
Antiplatelet activity in rabbit platelet rich plasma assessed as inhibition rate of ADP-induced platelet aggregation at 400 uM after 5 mins by aggregometry Oryctolagus cuniculus 55.31 %
Antiplatelet activity in rabbit platelet rich plasma assessed as inhibition rate of ADP-induced platelet aggregation at 200 uM after 5 mins by aggregometry Oryctolagus cuniculus 45.39 %
Antiplatelet activity in rabbit platelet rich plasma assessed as inhibition rate of ADP-induced platelet aggregation at 100 uM after 5 mins by aggregometry Oryctolagus cuniculus 27.26 %
Antiplatelet activity in rabbit platelet rich plasma assessed as inhibition rate of ADP-induced platelet aggregation at 50 uM after 5 mins by aggregometry Oryctolagus cuniculus 23.3 %
Antiplatelet activity in rabbit platelet rich plasma assessed as inhibition of ADP-induced aggregation at 0.05 mM treated for 5 mins prior to ADP-challenge relative to control Oryctolagus cuniculus 23.3 %
Antiplatelet activity in rabbit platelet rich plasma assessed as inhibition of ADP-induced aggregation at 0.1 mM treated for 5 mins prior to ADP-challenge relative to control Oryctolagus cuniculus 27.3 %
Antiplatelet activity in rabbit platelet rich plasma assessed as inhibition of ADP-induced aggregation at 0.4 mM treated for 5 mins prior to ADP-challenge relative to control Oryctolagus cuniculus 55.3 %
Antiplatelet activity in rabbit platelet rich plasma assessed as inhibition of ADP-induced aggregation at 0.2 mM treated for 5 mins prior to ADP-challenge relative to control Oryctolagus cuniculus 45.4 %
Anti-platelet activity in rabbit platelet-rich plasma assessed as inhibition of ADP-induced platelet aggregation at 100 uM incubated for 5 mins at 37 degC by aggregometry Oryctolagus cuniculus 36.8 %
Anti-platelet activity in rabbit platelet-rich plasma assessed as inhibition of ADP-induced platelet aggregation at 50 uM incubated for 5 mins at 37 degC by aggregometry Oryctolagus cuniculus 25.0 %
Anti-platelet activity in rabbit platelet-rich plasma assessed as inhibition of ADP-induced platelet aggregation at 25 uM incubated for 5 mins at 37 degC by aggregometry Oryctolagus cuniculus 4.8 %
Anti-platelet activity in rabbit platelet-rich plasma assessed as inhibition of ADP-induced platelet aggregation at 12.5 uM incubated for 5 mins at 37 degC by aggregometry Oryctolagus cuniculus 6.4 %
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate Severe acute respiratory syndrome coronavirus 2 26.77 % SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate Severe acute respiratory syndrome coronavirus 2 13.17 %
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus -0.04 % Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus 0.0 % Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus -0.04 % Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus 0.0 %
Inhibition of human CYP4Z1 expressed in permeabilized fission AZ3 yeast cells at 100 nM using luciferin-3FBE as substrate incubated for 3 hrs by luminescence based enzyme bag assay relative to control Homo sapiens 21.0 %
Inhibition of human CYP4Z1 overexpressed in human MCF7 cells at 1 uM using luciferin-3FBE as substrate incubated for 24 hrs followed by substrate addition by luminescence based assay relative to control Homo sapiens 24.0 %

Cross References

Resources Reference
ChEBI 134938
ChEMBL CHEMBL11662
DrugBank DB12017
DrugCentral 2043
FDA SRS L256JB984D
Guide to Pharmacology 9866
PubChem 5282440
SureChEMBL SCHEMBL4210
ZINC ZINC000000005389
CONTENTS